Larger and longer studies in broader populations are needed to fully understand the safety and efficacy in people with alcohol use disorder, but these initial findings are promising. About this study In addition to Hendershot and Klein, other authors of the study are Michael Bremmer, Michael Paladino, Georgios Kostantinis, Thomas Gilmore, Neil Sullivan, Amanda Tow and Robyn Jordan, all of University of North Carolina at Chapel Hill
Tirzepatide (which activates both GLP-1 and GIP receptors) has demonstrated superior weight loss and metabolic outcomes compared to semaglutide alone in clinical trials, with weight reductions exceeding 20% in some cohorts
Neurometabolic abnormalities in schizophrenia and depression observed with magnetic resonance spectroscopy at 7 T
Learn more in our injection pen guide for alternative delivery methods
Should I try Saxenda first before Ozempic since its been around longer